IL-6 Blocking Drug Ziltivekimab Enters Major Trial to Cut Heart Attack Risk
The ZEUS trial enrolls 6,376 high-risk patients to test whether blocking inflammation via IL-6 inhibition prevents cardiovascular events and kidney decline.
Summary
The ZEUS trial is a large, randomized, placebo-controlled study testing ziltivekimab — a monthly injectable IL-6 inhibitor — in 6,376 patients with atherosclerotic cardiovascular disease, chronic kidney disease, and elevated inflammation markers. Participants are elderly (mean age 69.5), predominantly hypertensive, and many have diabetes or heart failure. Baseline hsCRP of 4.5 mg/L and IL-6 of 4.9 pg/mL confirm significant systemic inflammation. The trial's primary endpoint is major adverse cardiovascular events (MACE), with secondary endpoints covering heart failure hospitalizations, all-cause mortality, and kidney function decline. Results could establish IL-6 inhibition as a novel cardiovascular prevention strategy for high-risk CKD patients.
Detailed Summary
Chronic inflammation is increasingly recognized as a root driver of atherosclerotic disease, beyond traditional risk factors like cholesterol. Interleukin-6 (IL-6) sits at the center of this inflammatory cascade, and blocking it has emerged as a promising therapeutic strategy. Patients with chronic kidney disease (CKD) are particularly burdened, carrying both elevated IL-6 levels and extraordinarily high cardiovascular risk.
The ZEUS trial (Ziltivekimab Cardiovascular Outcomes Trial) was designed to formally test whether monthly subcutaneous injections of ziltivekimab (15 mg) — a human monoclonal antibody targeting IL-6 — can reduce major cardiovascular events compared to placebo. The trial enrolled 6,376 participants across multiple countries in a 1:1 randomized, double-blind design, all of whom had established atherosclerotic cardiovascular disease, CKD, and hsCRP ≥2 mg/L.
At baseline, the cohort was high-risk: mean age 69.5, 92% hypertensive, 65.7% diabetic, 41.3% with heart failure, and mean eGFR of just 44.5 mL/min/1.73 m². LDL cholesterol was already well-managed at 77.7 mg/dL, underscoring that residual risk in this population is predominantly inflammation-driven rather than lipid-driven.
The primary outcome is 3-point MACE (MI, stroke, cardiovascular death). Secondary outcomes include expanded MACE, heart failure hospitalizations, all-cause mortality, and a kidney composite endpoint including ≥40% eGFR decline, dialysis, or transplant. This dual cardiovascular-renal focus is notable given CKD's role in amplifying inflammatory burden.
This is a design and baseline characteristics paper; efficacy results are pending. If ziltivekimab succeeds, it would represent the first IL-6 inhibitor approved for cardiovascular prevention — complementing statins and SGLT2 inhibitors with a wholly different mechanism targeting residual inflammatory risk.
Key Findings
- 6,376 patients with ASCVD, CKD, and hsCRP ≥2 mg/L randomized to ziltivekimab 15 mg monthly vs. placebo.
- Mean baseline eGFR was 44.5 mL/min/1.73 m², confirming advanced CKD in the trial population.
- Median hsCRP 4.5 mg/L and IL-6 4.9 pg/mL confirm high systemic inflammation despite standard-of-care therapy.
- LDL averaged 77.7 mg/dL, indicating residual risk is inflammatory, not primarily lipid-driven.
- Primary endpoint is 3-point MACE; secondary endpoints include kidney decline composite and all-cause mortality.
Methodology
ZEUS is a multinational, double-blind, placebo-controlled, event-driven randomized clinical trial with 1:1 allocation to ziltivekimab 15 mg subcutaneously monthly versus placebo. Enrollment required confirmed ASCVD, CKD, and hsCRP ≥2 mg/L. This publication reports rationale, design, and baseline characteristics only — efficacy data are forthcoming.
Study Limitations
This paper reports design and baseline data only; no efficacy or safety outcomes are yet available. The highly selected population — requiring both CKD and elevated hsCRP — may limit generalizability to lower-risk or non-CKD cardiovascular patients. As a pharma-sponsored trial (Novo Nordisk), commercial bias in reporting should be considered when results are published.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: